Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.67 |
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | MAOA | P21397 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | SNCA | P37840 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzphetamine SCHEMBL19285634 | 1.00 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL49120 | 1.00 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL6272098 | 0.98 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL265137 | 0.98 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL260091 | 0.98 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL28360250 | 0.98 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL4329836 | 0.96 | ADRA2B (0.92) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL15388333 | 0.93 | ADRA2B (0.86) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL12648381 | 0.83 | SLC6A2 (0.71) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL15003030 | 0.83 | ADRA2B (0.71) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240286993-A1 | Non-distillative Process for Manufacturing High Purity Amphetamines | Pharmapotheca A, Inc. | 2024-08-29 | — | — | US | disclosed |
| WO-2024175957-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20070129444-A1 | Novel weight reduction composition and uses thereof | MALLINCKRODT INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006060099-A1 | CRYSTALLIZATION METHOD FOR BENZPHETAMINE | MALLINCKRODT INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006057778-A2 | PROCESS FOR THE PURIFICATION OF BENZPHETAMINE HYDROCHLORIDE | MALLINCKRODT INC. (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | SLC6A2 2/4885ADRA2B 72/4885ADRA2C 80/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | SLC6A2 330/4885ADRA2B 518/4885ADRA2C 571/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | SLC6A2 2832/4885ADRA2B 3274/4885ADRA2C 3410/4885 |
| US-20240286993-A1 | Non-distillative Process for Manufacturing High Purity Amphetamines | AASDHPPT, AADAT, SLC6A3 | SLC6A2 30/4885ADRA2B 1011/4885ADRA2C 868/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885ADRA2B 95/4885ADRA2C 111/4885 |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | SMS, SRMS, SRM | SLC6A2 12/4885ADRA2B 390/4885ADRA2C 157/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885ADRA2B 95/4885ADRA2C 111/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A2 1348/4885ADRA2B 374/4885ADRA2C 301/4885 |
| US-20070129444-A1 | Novel weight reduction composition and uses thereof | HCRTR1, GPR119, HCRTR2 | SLC6A2 163/4885ADRA2B 171/4885ADRA2C 200/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885ADRA2B 111/4885ADRA2C 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.